Sangamo Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.02.20	Stock Alert: Sangamo Therapeutics Up 28% (RTTNews)
28.02.20	Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results (Businesswire)
28.02.20	FDA Nod For BHVN's Drug, IBIO On Watch, SGMO Soars On Biogen Deal (RTTNews)
27.02.20	Biogen, Sangamo Sign Deal To Develop Gene Therapies For Neurological Diseases (RTTNews)
27.02.20	Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases (Businesswire)
25.02.20	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast (Businesswire)
12.02.20	Sangamo Therapeutics Appoints John Markels to Its Board of Directors (Businesswire)
09.01.20	Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference (Businesswire)
23.12.19	Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment (Businesswire)
17.12.19	Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day (Businesswire)
08.12.19	At The ASH 2019 Annual Meeting: AXLA, CBMG, SRRA, EPZM, STOK... (RTTNews)
07.12.19	Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment (Businesswire)
06.12.19	Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day (Businesswire)
26.11.19	Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors (Businesswire)
19.11.19	Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation (Businesswire)
18.11.19	Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference (Businesswire)
08.11.19	Sangamo Therapeutics Announces New Scientific Advisory Board (Businesswire)
06.11.19	Sangamo Therapeutics Reports Third Quarter 2019 Financial Results (Businesswire)
06.11.19	Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting (Businesswire)
01.11.19	Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer (Businesswire)
30.10.19	Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast (Businesswire)
30.09.19	Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer (Businesswire)
30.09.19	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Businesswire)
30.08.19	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Businesswire)
07.08.19	Sangamo Therapeutics Reports Second Quarter 2019 Financial Results (Businesswire)
06.08.19	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Businesswire)
31.07.19	Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel (Businesswire)
31.07.19	Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast (Businesswire)
29.07.19	Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases (Businesswire)
06.07.19	Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels (Businesswire)
01.07.19	Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease (Businesswire)
05.04.19	MACK Halts MM-310 Study, VKTX On Watch, NAII Hits New High (RTTNews)
03.04.19	5 Top Gainers In Healthcare Sector (AVEO, EDAP, ZYNE...) (RTTNews)
02.04.19	Sangamo, Pfizer Report Promising Interim Results With SB-525 Gene Therapy (RTTNews)
02.02.19	Week Ahead In Pharmaceuticals: 6 Stocks To Watch (EOLS, AVRO, SGMO...) (RTTNews)
10.01.19	10 Gene Therapy Companies Unignorable In 2019 (RTTNews)
10.01.19	5 Top Losers In Healthcare Sector (RHE, MBOT, AKRX...) (RTTNews)
23.07.18	TxCell Stock Surges On Deal To Be Bought By US-based Sangamo (RTTNews)
21.06.18	In The Spotlight: Sangamo Therapeutics (RTTNews)
04.06.18	Sangamo Announces U.K. Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatments SB-318 For MPS I And SB-913 For MPS II (PR Newswire)
30.05.18	Sangamo Therapeutics Announces Presentation At The 2018 Jefferies Global Healthcare Conference (PR Newswire)
08.05.18	Sangamo Therapeutics Reports First Quarter 2018 Financial Results (PR Newswire)
03.05.18	Sangamo Therapeutics Announces Senior Leadership Changes (PR Newswire)
03.05.18	Medizone International and Innovasource Implement & Expand Exclusive AsepticSure® Product Evaluation Agreement (PR Newswire)
01.05.18	Sangamo Therapeutics Announces First Quarter 2018 Conference Call and Webcast (PR Newswire)
01.05.18	Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy (PR Newswire)
27.04.18	Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Transfusion-Dependent Beta-Thalassemia (PR Newswire)
04.04.18	Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program (PR Newswire)
05.03.18	Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences (PR Newswire)
02.03.18	Sangamo Therapeutics, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Zuversicht in New York: So bewegt sich der NASDAQ Composite aktuell
19.12.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite zum Start mit Gewinnen
18.12.24		Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu
18.12.24		Börsianer warten auf Impulse: NASDAQ Composite kaum bewegt
18.12.24		Handel in New York: NASDAQ Composite legt zu
18.12.24		Zuversicht in New York: Anleger lassen NASDAQ Composite zum Handelsstart steigen
17.12.24		Schwacher Handel in New York: NASDAQ Composite legt schlussendlich den Rückwärtsgang ein
16.12.24		Freundlicher Handel in New York: NASDAQ Composite schlussendlich fester

20.12.24

Zuversicht in New York: So bewegt sich der NASDAQ Composite aktuell

19.12.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite zum Start mit Gewinnen

18.12.24

Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu

18.12.24

Börsianer warten auf Impulse: NASDAQ Composite kaum bewegt

18.12.24

Handel in New York: NASDAQ Composite legt zu

18.12.24

Zuversicht in New York: Anleger lassen NASDAQ Composite zum Handelsstart steigen